Asset
BEZUCLASTINIB
COGENT BIOSCIENCES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04996875 | phase2 | recruiting | 2021-11-09 | 2025-09-19 | Cogent Biosciences, Inc. | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis |
| NCT05208047 | phase3 | recruiting | 2022-04-14 | 2025-09-30 | Cogent Biosciences, Inc. | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
| NCT02401815 | phase1_2 | completed | 2015-03-06 | 2020-05-11 | Cogent Biosciences, Inc. | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.